SCHEMBL570862

SCHEMBL570862

CC(C)(C)OC(=O)N1CC(C(O)C(=O)O)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 1/20 0.40
RORC P51449 1/20 0.39
IDO1 P14902 1/20 0.39
GPR119 Q8TDV5 1/20 0.38
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38
PDE4B Q07343 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
NAMPT P43490 1/20 0.37
USP30 Q70CQ3 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150140 0.86 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL30922891 0.85 MEN1 (0.49) USP2SMN1; SMN2HPGDGPR119EPHX1
SCHEMBL23880037 0.84 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL7141709 0.83 HPGD (0.51) USP2SMN1; SMN2HPGDGPR119RECQL
SCHEMBL12179693 0.83 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL3036029 0.82 NR1H2 (0.50) NR1H2USP2SMN1; SMN2HPGDIDO1
SCHEMBL4546637 0.80 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL4415868 0.80 NR1H2 (0.45) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL2673596 0.79 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL10190233 0.79 NR1H2 (0.50) NR1H2USP2SMN1; SMN2HPGDRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115803030-A Compounds and methods for KRAS-targeted degradation 阿维纳斯企业公司 2023-03-14 CN disclosed
US-11117915-B2 Antibacterial aminoglycoside analogs Cipla USA, Inc. (US) 2021-09-14 US disclosed
US-11117915-B2 Antibacterial aminoglycoside analogs Cipla USA, Inc. (US) 2021-09-14 US disclosed
US-20200317709-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. 2020-10-08 US disclosed
US-20200317709-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. 2020-10-08 US disclosed
CN-106188175-B Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds 轩竹(北京)医药科技有限公司 2020-08-11 CN disclosed
EP-3150617-B1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS CIPLA USA INC (US) 2020-04-08 EP disclosed
US-RE47741-E1 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2019-11-26 US disclosed
US-RE47741-E1 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2019-11-26 US disclosed
US-9688711-B2 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2017-06-27 US disclosed
EP-2217610-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Achaogen, Inc. (US) 2010-08-18 EP disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
WO-2010042850-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2010042850-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2010042851-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2010042851-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 WO disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317709-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 NR1H2 1577/4885USP2 3805/4885SMN1; SMN2 2895/4885
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 NR1H2 1577/4885USP2 3805/4885SMN1; SMN2 2895/4885
US-11117915-B2 Antibacterial aminoglycoside analogs MRPL21, MRPL9, NQO2 NR1H2 1577/4885USP2 3805/4885SMN1; SMN2 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.